MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the quarter ending 2025-09-30, MIST had $4,186K increase in cash & cash equivalents over the period. -$9,750K in free cash flow.

Cash Flow Overview

Change in Cash
$4,186K
Free Cash flow
-$9,750K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
    • Proceeds from issuance of common...
    • Proceeds from issuance of common...
    • Proceeds from issuance of common...
    • Others
Negative Cash Flow Breakdown
    • Acquisition of short-term invest...
    • Prepaid expenses
    • Operating lease assets and liabi...
    • Acquisition of property and equi...

Cash Flow
2025-09-30
2025-06-30
Net loss
-11,922 -33,727
Depreciation of property and equipment
25 55
Amortization of debt costs
109 208
Accretion of investment discount
0 -81
Non-cash interest expense related to debt
859 1,678
Share-based compensation expense
1,250 2,659
Other receivables
-224 -566
Research and development tax credits receivable
-271 178
Prepaid expenses
1,829 -1,092
Operating lease assets and liabilities
-8 -3
Accounts payable and accrued liabilities
1,273 1,213
Net cash used in operating activities
-9,748 -26,518
Acquisition of property and equipment
2 17
Acquisition of short-term investments
34,982 922
Redemption of short-term investments
0 -44,466
Net cash provided by (used in) investing activities
-34,984 43,527
Proceeds from exercise of options
122 36
Proceeds from issuance of common shares, net of issuance costs
23,143 -
Proceeds from issuance of pre-funded warrants, net of issuance costs
-2,573 -
Proceeds from issuance of common stock warrants, net of issuance costs-Seriesa Common Warrants
9,504 -
Proceeds from issuance of common stock warrants, net of issuance costs-Seriesb Common Warrants
13,416 -
Proceeds from employee stock purchase plan
160 140
Cash provided by financing activities
48,918 176
Net increase (decrease) in cash and cash equivalents
4,186 17,185
Cash and cash equivalents at beginning of period
25,314 -
Cash and cash equivalents at end of period
46,685 -
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.

Time Plot

Show the time plot by selecting a row from the table.

Cash Flow

Proceeds from issuance ofcommon shares, net of...$23,143K Proceeds from issuance ofcommon stock warrants,...$13,416K Proceeds from issuance ofcommon stock warrants,...$9,504K Proceeds from issuance ofpre-funded warrants, net of...-$2,573K Proceeds from employeestock purchase plan$160K Proceeds from exercise ofoptions$122K Cash provided byfinancing activities$48,918K Net increase(decrease) in cash and cash...$4,186K Canceled cashflow$44,732K Accounts payable andaccrued liabilities$1,273K Share-based compensationexpense$1,250K Non-cash interestexpense related to debt$859K Research and developmenttax credits...-$271K Other receivables-$224K Amortization of debt costs$109K Depreciation of property andequipment$25K Net cash provided by(used in) investing...-$34,984K Net cash used inoperating activities-$9,748K Canceled cashflow$4,011K Acquisition of short-terminvestments$34,982K Acquisition of property andequipment$2K Net loss-$11,922K Prepaid expenses$1,829K Operating lease assets andliabilities-$8K

Milestone Pharmaceuticals Inc. (MIST)

Milestone Pharmaceuticals Inc. (MIST)